Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and drastically improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life that prevent infections and the diseases associated with chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, others are administered at the discretion of the prescribing physician and patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Despite notable competition, both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options.

QUESTIONS ANSWERED

  • What are the sizes of the populations eligible for key vaccination programs in the G7?
  • Who are the key decision-makers for vaccine purchasing and administration, and how does this role vary by geography?
  • What are the key drivers of brand preference in a given vaccine market?
  • For which pathogens is unmet need greatest for a new or improved vaccine? Which patient pools do experts indicate will be eligible for these vaccines?
  • How will the current vaccine pipeline fulfill areas of unmet need in the vaccine market?
  • How will key current and emerging vaccines perform commercially?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Emerging Vaccines - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Overview
          • HPV Vaccine Eligible Adult Female Population per 1,000 People in 2018 and 2038
          • HPV Vaccine Eligible Adult Male Population per 1,000 People in 2018 and 2038
          • HPV Vaccine Eligible Adolescent Female Population per 1,000 People in 2018 and 2038
          • HPV Vaccine Eligible Adolescent Male Population per 1,000 People in 2018 and 2038
          • HBV Eligible Pediatric Population per 1,000 people in 2018 and 2038
          • HBV Vaccine Eligible Adolescent and Adult Population per 1,000 people in 2018 and 2038
          • RSV Adult Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • RSV Adult Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • RSV Maternal Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • RSV Maternal Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • RSV Pediatric Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • Shingles Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • Influenza Vaccine Eligible Population per 1,000 people in 2018 and 2038
          • Pneumococcal Vaccine Eligible Population per 1,000 People in 2018 and 2038
          • Meningococcal B Vaccine Eligible Population per 1,000 People in 2018 and 2038
          • Meningococcal ACWY Vaccine Eligible Population per 1,000 People in 2018 and 2038
      • Epidemiology Data
      • Methods
        • HBV Vaccine Eligible Population
        • HPV Vaccine Eligible Population
        • Influenza Vaccine Eligible Population
        • Pneumococcal Vaccine Eligible Population
        • RSV Vaccine Eligible Population
        • Shingles Vaccine Eligible Population
        • Meningococcal ACWY Vaccine Eligible Population
        • Meningococcal B Vaccine Eligible Population
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Emerging Vaccines Eligible Population
          • Studies Excluded from the Analysis of Emerging Vaccines
        • Risk/Protective Factors
          • Risk/Protective Factors for [Indication]
        • Bibliography

    Author(s): Alison Isherwood, MSc, MRes, PhD; Sandeep Mahapatra, BDS, MPH

    Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.

    Sandeep is a dental graduate with a Master’s in Public Health with a specialization in Epidemiology and has been associated with DRG since June 2018. He works with a global team of epidemiologists in performing fully documented systematic reviews of published and grey literature on epidemiology of diseases and their risk factors. He also conducts analysis on descriptive epidemiology of major indications in mature and developing markets. Additionally, he supports the operational and strategic management of the team and wider business unit through collation of data from various sources.

    Prior to joining DRG he had over 5 years of experience working with state and central government of India to plan, design and conduct large scale research and implementation projects on non-communicable diseases, tobacco cessation and childhood nutrition.